NCT03363763 - Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

March 24, 2023

Study Completion Date

March 24, 2023

Conditions

Angiofibroma of FaceTuberous Sclerosis

Interventions

DRUG

Sirolimus 0.2%

Ointment for topical administration hs x 12 weeks

DRUG

Sirolimus 0.4%

Ointment for topical administration hs x 12 weeks

DRUG

Placebo ointment

Placebo ointment comparator for topical administration hs x 12 weeks

Trial Locations (8)

Children's Hospital of Philadelphia, Philadelphia

Children's Healthcare of Atlanta, Atlanta

LeBonheur Children's Hospital, Memphis

Children's Clinical Research Organization, Children's Hospital Colorado, Aurora

Translational Genomics Research, Phoenix

Children's Hospital of Los Angeles, Division of Neurology, Los Angeles

Children's Hospital of Fudan University, Shanghai

Boston Children's Hospital, Boston